Myeloma Highlights from ASH 2015 Conference

| Jack Aiello

This is my tenth year attending ASH (American Society of Hematology), where 25,000 attendees from all over the world (hematologists/oncologists, lab researchers, oncology nurses, scientists & 300 pharma companies) present the latest research results during both oral presentations (1000) as well as on posters (3000) that cover all blood cancers. This year there were nearly […]

Vampire Convention

| John Auerbacher

Vampire Convention I explained to my daughter that I was going to a blood convention. Saturday, December 5, 2015 The Orange County Convention Center is the longest building I have ever hiked. Envision airline terminals. My new SGL (“Support Group Leaders”) friends joke about leashing ourselves together, though no one has yet gotten lost (including […]

My Favorite Moment at ASH 2015

| Carlene Pratt

I thoroughly enjoyed hearing Dr. Brian Durie’s abstract presentation on “Myeloma: Therapy, excluding Transplantation: Advances in Newly Diagnosed and Relapsed Myeloma.”  He presented that the combination of VELCADE® (bortezomib), Revilmid® (lenalidomide), and dexamethasone (also called VRd), with continuous maintenance of lenalidomide and dexamethasone significantly improves progression-free survival and overall survival. This VRd regimen along with […]

Hooray for the IMF

| Tom Swick

I am very grateful to the International Myeloma Foundation (IMF) for giving me the opportunity to attend the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando. It is one thing to read the abstracts and wait for the webcast summaries, but quite another to experience the dynamics of the hematology experts […]

Post-ASH 2015: A Time to Reflect

| Jim Barth

As four hectic days of symposiums, education sessions, poster sessions, oral sessions, interrupted only by working breakfasts and lunches, as well as shuttles back and forth to our temporary beds came to a close, it was time to reflect. This is a tough schedule for multiple myeloma patients who double as a support group leaders. […]

ASH 2015: Wow – What a Meeting!

| Linda Huguelet

Trying to process all of the information that I heard at The American Society of Hematology (ASH) Conference is a bit overwhelming. But, the one thing I can say (without looking at my many pages of notes) is that advances in multiple myeloma treatments are on the fast-track and a countless number of researchers are […]

IMF’s Grant Reception

| Michael Tuohy

On Saturday evening, the IMF holds their Annual Grant Reception where there is a mix of researchers, doctors, nurses, pharma partners, and patients! This is a very unique opportunity for patients to mingle and ask questions from those involved in multiple myeloma from bench to bedside. This evening is where the IMF presents their Annual […]

ASH 2015: And That’s a Wrap!

| Robin Tuohy

Well, I’m back home writing this blog, and ASH was a whirlwind of presentations, events, and networking. My brain is on overdrive, but it’s all good!  I’ve gone through miles of my notes and pictures; and for this last blog, I will focus on on Monday, Dec 7th—my last day at ASH. Please check out […]

Impressions from ASH 2015

| Jim Omel

Reflecting back on what we saw and heard at ASH 15, IMF support group leaders (SGLs) left Orlando with great hope for success against myeloma. Three new drug approvals in the two weeks preceding ASH were the talk of the meeting. Direct attack on myeloma cells by monoclonal antibodies gives us a new weapon with […]